comparemela.com

Latest Breaking News On - Aacr annual meeting - Page 1 : comparemela.com

Nivolumab Plus Talazoparib Does Not Induce Responses in Heavily Pretreated Melanoma

Nivolumab plus talazoparib did not produce RECIST-based tumor responses in heavily pretreated patients with unresectable or metastatic melanoma.

United statesJames isaacsDepartment of hematologyMedical oncologyCleveland clinicCleveland clinic gross family melanoma registryNivolumab plus talazoparibAacr annual meeting

Proteogenomic Signatures Shed Light on Prostate Cancer Recurrence Risk in Select Ancestries

A proteomics analysis revealed significant variations in protein expression and informative markers between African vs European prostate tumors.

United statesSouth koreaCara schaferProstate disease researchDepartment of surgeryUniformed services university of the health sciencesHenrym jackson foundationResearch networkJohnp murtha cancer centerWalter reed national military medical centerUniformed services universityHealth sciencesApplied proteogenomic organizational learningCancer centerWalter reed national military medicalShyh han tan

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.

United statesEbrahim delpassandNuclear oncology centerEnrollment criteriaExcel diagnosticsAacr annual meetingProstate cancerFpi 2265Phase 2 tatcist trial nct05219500

Novel CAR T-Cell Therapy HR001 Demonstrates Efficacy in R/R Non-Hodgkin Lymphoma

The novel CAR T-cell agent HR001 was effective, with durable responses and a favorable safety profile observed, in relapsed/refractory non-Hodgkin lymphoma.

Yian zhangZhongshan hospital fudan universityAacr annual meeting

RGI-2001 Plus Tacrolimus/Methotrexate Demonstrates Protective Effect From Acute GVHD Post Allo-HSCT

Prophylactic treatment with RGI-2001 plus tacrolimus and methotrexate led to a lower incidence of acute GVHD vs CIBMTR control following allo-HSCT.

Calvink leeAacr annual meetingRgi 2001Hematologic oncologyPhase 2b rgi 2001 301 trial nct04014790

vimarsana © 2020. All Rights Reserved.